Literature DB >> 17513199

Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders.

Tomas Palomo1, Richard M Kostrzewa, Richard J Beninger, Trevor Archer.   

Abstract

Psychiatric disorders may co-occur in the same individual. These include, for example, substance abuse or obsessive-compulsive disorder with schizophrenia, and movement disorders or epilepsy with affective dysfunctional states. Medications may produce iatrogenic effects, for example cognitive impairments that co-occur with the residual symptoms of the primary disorder being treated. The observation of comorbid disorders in some cases may reflect diagnostic overlap. Impulsivity, impulsiveness or impulsive behaviour is implicated in a range of diagnostic conditions including substance abuse, affective disorder and obsessive-compulsive disorder. These observations suggest a need to re-evaluate established diagnostic criteria and disorder definitions, focusing instead on symptoms and symptom-profiles.

Entities:  

Mesh:

Year:  2007        PMID: 17513199     DOI: 10.1007/BF03033900

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  199 in total

1.  Dissociable neural responses to facial expressions of sadness and anger.

Authors:  R J Blair; J S Morris; C D Frith; D I Perrett; R J Dolan
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

2.  FACTOR ANALYSIS OF SOME PSYCHOMETRIC MEASURES OF IMPULSIVENESS AND ANXIETY.

Authors:  E S BARRATT
Journal:  Psychol Rep       Date:  1965-04

Review 3.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Authors:  Moussa B H Youdim; Tamar Amit; Orit Bar-Am; Orly Weinreb; Mara Yogev-Falach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder.

Authors:  A Raine; T Lencz; S Bihrle; L LaCasse; P Colletti
Journal:  Arch Gen Psychiatry       Date:  2000-02

Review 5.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

6.  Electrophysiological substrates of impulsiveness: potential effects on aggressive behavior.

Authors:  Rebecca J Houston; Matthew S Stanford
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12-28       Impact factor: 5.067

7.  Neurobiological substrates of antisocial and borderline personality disorder: preliminary results of a functional fMRI study.

Authors:  Birgit Völlm; Paul Richardson; John Stirling; Rebecca Elliott; Mairead Dolan; Imran Chaudhry; Christina Del Ben; Shane McKie; Ian Anderson; Bill Deakin
Journal:  Crim Behav Ment Health       Date:  2004

Review 8.  Central serotonin and impulsive aggression.

Authors:  E F Coccaro
Journal:  Br J Psychiatry Suppl       Date:  1989-12

Review 9.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

Review 10.  Group treatment for smoking cessation among persons with schizophrenia.

Authors:  J Addington
Journal:  Psychiatr Serv       Date:  1998-07       Impact factor: 3.084

View more
  9 in total

1.  Cognitive symptoms facilitatory for diagnoses in neuropsychiatric disorders: executive functions and locus of control.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

2.  Affective personality as cognitive-emotional presymptom profiles regulatory for self-reported health predispositions.

Authors:  T Archer; B Adolfsson; E Karlsson
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

3.  Affective status in relation to impulsive, motor and motivational symptoms: personality, development and physical exercise.

Authors:  Tomas Palomo; Richard J Beninger; Richard M Kostrzewa; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

4.  Focusing on symptoms rather than diagnoses in brain dysfunction: conscious and nonconscious expression in impulsiveness and decision-making.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

5.  Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry.

Authors:  Trevor Archer; Marlene Oscar-Berman; Kenneth Blum; Mark Gold
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-30

6.  Epigenetic Modulation of Mood Disorders.

Authors:  T Archer; M Oscar-Berman; K Blum; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-02-11

7.  The affective profiles in the USA: happiness, depression, life satisfaction, and happiness-increasing strategies.

Authors:  Erica Schütz; Uta Sailer; Ali Al Nima; Patricia Rosenberg; Ann-Christine Andersson Arntén; Trevor Archer; Danilo Garcia
Journal:  PeerJ       Date:  2013-09-10       Impact factor: 2.984

8.  The affective profiles, psychological well-being, and harmony: environmental mastery and self-acceptance predict the sense of a harmonious life.

Authors:  Danilo Garcia; Ali Al Nima; Oscar N E Kjell
Journal:  PeerJ       Date:  2014-02-13       Impact factor: 2.984

9.  Two different approaches to the affective profiles model: median splits (variable-oriented) and cluster analysis (person-oriented).

Authors:  Danilo Garcia; Shane MacDonald; Trevor Archer
Journal:  PeerJ       Date:  2015-10-29       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.